Class Action Dilemmas: Pursuing Public Goals for Private Gain

By Deborah R. Hensler; Nicholas M. Pace et al. | Go to book overview
Save to active project

Chapter Eleven BLOOD CLOTTING PRODUCTS FOR HEMOPHILIACS: 1
IN RE FACTOR VIII OR IX CONCENTRATE BLOOD PRODUCTS 2

PROLOGUE

In the early 1980s, at the advent of the AIDS epidemic, the supply of plasma used to manufacture factor concentrate, a blood product used by hemophiliacs to facilitate clotting, became infected with human immunodeficiency virus (HIV.). Eventually, factor concentrate transmitted the virus to more than half of the 16,000 persons with hemophilia in the United States. 3 Soon after, lawsuits against the manufacturers of factor concentrate arose across the country in state and federal courts, as both individual cases and class actions. The case presented here was intended to resolve all of the nationwide litigation in a single class action, and it has followed a particularly complicated course. After the initial complaint was filed, this lawsuit was certified as a class action, decertified by the Seventh Circuit Court of Appeals, and once again certified as a class action for purposes of settlement.


A Medical Breakthrough

Hemophilia, a disease afflicting males that is inherited from their mothers, is marked by spontaneous, uncontrollable internal and external bleeding that is caused by a lack of the proteins necessary for blood clotting. Internal bleeding into joints or organs may result in death or disability. External bleeding can also be fatal if the sufferer loses an excessive amount of blood.

In 1964 a process was developed to extract clotting agents from healthy human blood. The resulting extract, known as cryoprecipitate, is administered by transfusion to facilitate the clotting necessary to prevent excessive blood loss and permanent damage to the nerves, muscles, and organs. 4 The development of cryoprecipitate was a step forward in the treatment of hemophilia, but there were drawbacks to its use. To prevent excessive blood loss, the patient needed to receive an injection of cryoprecipitate at the first sign of a bleeding spell; however, patients could not self-administer the treatment. If a bleeding spell

-293-

Notes for this page

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this page

Cited page

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited page

Bookmark this page
Class Action Dilemmas: Pursuing Public Goals for Private Gain
Table of contents

Table of contents

Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this book

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen
/ 609

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?